A Randomized, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in Subjects With T2DM Treated With Metformin.
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2016
At a glance
- Drugs AZD 1656 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 20 Aug 2010 New source identified and integrated (Clinical Trials Registry - India record CTRI2009-091-000774).
- 15 Jan 2010 Actual patient number (70) added as reported by ClinicalTrials.gov.
- 15 Jan 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.